Literature DB >> 8500885

Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites.

M Ak1, J H Bower, S L Hoffman, M Sedegah, A Lees, M Carter, R L Beaudoin, Y Charoenvit.   

Abstract

Passive transfer of monoclonal antibodies (MAbs) against malaria circumsporozoite (CS) proteins protects animals against malaria. Active immunization with synthetic or recombinant peptides induces a level of polyclonal antibodies to sporozoites comparable to those found after passive immunization but does not provide comparable protection. In the Plasmodium yoelii system, synthetic or recombinant peptide-induced antibodies have never been shown to protect. The current studies were designed to determine whether immunogen structure (native protein versus synthetic peptide) or immunoglobulin G (IgG) subclass of antibodies was responsible for the absolute differences between protective, passively transferred MAbs and nonprotective, actively induced polyclonal antibodies. In this study we produced two MAbs, QGP-S1 (IgG1) and QGP-S2 (IgG2b), by immunization with a synthetic peptide based on the P. yoelii CS major repeat, (QGPGAP)4, conjugated to keyhole limpet hemocyanin. These MAbs were compared tp NYS1 (IgG3), an anti-CS protein MAb previously produced by immunization with irradiated P. yoelii sporozoites, which recognizes (QGP GAP)2. QGP-S1 and QGP-S2 passively transferred protection. However, when compared with NYS1, there was a hierarchy of protection, NYS1 > QGP-S1 > QGP-S2. There was no correlation between antibody level at challenge as determined by immunofluorescent antibody test against sporozoites or enzyme-linked immunosorbent assay against (QGPGAP)2 or apparent antibody avidity for (QGPGAP)2 by sodium thiocyanate elution assay. The data demonstrate that a synthetic peptide can induce protective antibodies and that a specific antibody subclass is not required for protection. Work to determine whether antibody affinity or fine specificity can explain the hierarchy of protection among the MAbs is under way.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500885      PMCID: PMC280874          DOI: 10.1128/iai.61.6.2493-2497.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Antibody avidity determination by ELISA using thiocyanate elution.

Authors:  G R Pullen; M G Fitzgerald; C S Hosking
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

3.  Production of monoclonal antibodies by hybridomas sensitized to sporozoites of Plasmodium berghei.

Authors:  H D Danforth; G H Campbell; M F Leef; R L Beaudoin
Journal:  J Parasitol       Date:  1982-12       Impact factor: 1.276

4.  Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.

Authors:  J E Egan; J L Weber; W R Ballou; M R Hollingdale; W R Majarian; D M Gordon; W L Maloy; S L Hoffman; R A Wirtz; I Schneider
Journal:  Science       Date:  1987-04-24       Impact factor: 47.728

5.  In vivo testing of subunit vaccines against malaria sporozoites using a rodent system.

Authors:  A A Lal; V F de la Cruz; M F Good; W R Weiss; M Lunde; W L Maloy; J A Welsh; T F McCutchan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity.

Authors:  M Sedegah; C H Chiang; W R Weiss; S Mellouk; M D Cochran; R A Houghten; R L Beaudoin; D Smith; S L Hoffman
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

7.  Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens.

Authors:  Y Charoenvit; M F Leef; L F Yuan; M Sedegah; R L Beaudoin
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

8.  Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax.

Authors:  W E Collins; R S Nussenzweig; W R Ballou; T K Ruebush; E H Nardin; J D Chulay; W R Majarian; J F Young; G F Wasserman; I Bathurst
Journal:  Am J Trop Med Hyg       Date:  1989-05       Impact factor: 2.345

9.  Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria.

Authors:  J P Tam; P Clavijo; Y A Lu; V Nussenzweig; R Nussenzweig; F Zavala
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection.

Authors:  P Potocnjak; N Yoshida; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  12 in total

1.  Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes.

Authors:  Y Charoenvit; V Fallarme; W O Rogers; J B Sacci; M Kaur; J C Aguiar; L F Yuan; G Corradin; E Andersen; B Wizel; R A Houghten; A Oloo; P De la Vega; S L Hoffman
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

2.  Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.

Authors:  Giane A Oliveira; Kristiane Wetzel; J Mauricio Calvo-Calle; Ruth Nussenzweig; Annette Schmidt; Ashley Birkett; Filip Dubovsky; Eveline Tierney; Christoph H Gleiter; Gabriele Boehmer; Adrian J F Luty; Michael Ramharter; George B Thornton; Peter G Kremsner; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo.

Authors:  S Gantt; C Persson; K Rose; A J Birkett; R Abagyan; V Nussenzweig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Circumsporozoite protein as a potential target for antimalarials.

Authors:  Cristina Fernández-Arias; Sara Mashoof; Jing Huang; Moriya Tsuji
Journal:  Expert Rev Anti Infect Ther       Date:  2015-06-16       Impact factor: 5.091

5.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

Review 6.  Malaria vaccine development.

Authors:  T R Jones; S L Hoffman
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

7.  Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum.

Authors:  Brandon K Sack; Jessica L Miller; Ashley M Vaughan; Alyse Douglass; Alexis Kaushansky; Sebastian Mikolajczak; Alida Coppi; Gloria Gonzalez-Aseguinolaza; Moriya Tsuji; Fidel Zavala; Photini Sinnis; Stefan H I Kappe
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

8.  SHIV antigen immunization alters patterns of immune responses to SHIV/malaria coinfection and protects against life-threatening SHIV-related malaria.

Authors:  James T Frencher; Bridgett K Ryan-Pasyeur; Dan Huang; Ri Cheng Wang; Phillip D McMullen; Norman L Letvin; William E Collins; Nancy E Freitag; Miroslav Malkovsky; Crystal Y Chen; Ling Shen; Zheng W Chen
Journal:  J Infect Dis       Date:  2013-04-08       Impact factor: 5.226

9.  An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.

Authors:  Carlos A Parra-López; David Bernal-Estévez; Liusong Yin; Luis Eduardo Vargas; Carolina Pulido-Calixto; Luz Mary Salazar; J Mauricio Calvo-Calle; Lawrence J Stern
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

10.  Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes.

Authors:  F Schödel; R Wirtz; D Peterson; J Hughes; R Warren; J Sadoff; D Milich
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.